8-K filed Jul 24, 2026 at 16:01 ET
MannKind raised $50M via a private placement of 10.4M shares at $3.89/share and 2.4M pre-funded warrants at $3.88/share, with proceeds earmarked for general corporate purposes including a $45M CVR payment triggered by the FDA approval of Furoscix ReadyFlow. The FDA approval of Furoscix ReadyFlow for edema in heart failure or chronic kidney disease is a significant regulatory milestone that validates the company's pipeline and triggers the CVR liability. The combination of dilutive financing to meet a known obligation and a major product approval creates a mixed picture: the approval is a clear positive catalyst, but the immediate need to raise capital at a discount to fund the associated CVR payment tempers the bullish sentiment and signals potential cash constraints.